Fig. 4 | Nature Communications

Fig. 4

From: Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms

Fig. 4

VSVΔM51 promotes T-cell accumulation within tumors and serves as a systemic immune system adjuvant. a Expression levels of T-cell promoting chemokines and cytokines within the interstitial fluid of EMT6 tumors, measured by Luminex (duplicate experiments; mean ± SD; ANOVA with Tukey’s multiple comparisons test). b CD8+ T cells within EMT6 tumors 7 days post treatment, measured by flow cytometry (triplicate experiments; mean ± SD; ANOVA with Tukey’s multiple comparisons test). c Intracellular staining for IFNγ or TNFα within CD8+ T cells isolated from EMT6 tumors 7 days post treatment and stimulated with PMA and ionomycin ex vivo, measured by flow cytometry (duplicate experiment; mean ± SD; ANOVA with Tukey’s multiple comparisons test). d Intracellular staining for arginase-1 in CD11b+MHC-II±Ly6C± TAMs isolated from EMT6 tumors 72 h post treatment (single experiment; mean ± SD; t-test). e Activation of CD8+ T cells isolated from EMT6 tumors 8 days post treatment, after co-culture with EMT6 cells, measured by IFNγ ELISpot assay (single experiment; mean ± SD; t-test). f Representative IVM images of VSVΔM51-GFP infection of TdLN and spleen, taken 8 h post-VSVΔM51-GFP treatment (n = 3 biological replicates). Scale bars for TdLN and spleen = 250 μM and 50 μM, respectively. g Cytokines within blood taken from EMT6 tumor-bearing mice treated with VSVΔM51, measured by Luminex (single experiment; mean ± SD; ANOVA with Tukey’s multiple comparisons test)

Back to article page